Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KY-226 是选择性的,口服活性的和变构蛋白酪氨酸磷酸酶 1B 抑制剂,IC50=0.25 μM,且不激活 PPARγ 。它可以保护神经元免受脑缺血损伤。它通过增强胰岛素和瘦素信号传导发挥抗糖尿病和抗肥胖作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 997 | 现货 | ||
5 mg | ¥ 2,330 | 现货 | ||
10 mg | ¥ 3,920 | 现货 | ||
25 mg | ¥ 6,290 | 现货 | ||
50 mg | ¥ 8,630 | 现货 | ||
100 mg | ¥ 11,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 931 | 现货 |
产品描述 | KY-226 is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B)(IC50: 0.25 μM,) |
靶点活性 | PTP1B:0.25 μM |
体内活性 | In db/db mice, the oral administration of KY-226 (10 and 30 mg/kg/day, 4 weeks) significantly reduced plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain, while pioglitazone exerted similar effects with increases in body weight gain.?KY-226 attenuated plasma glucose elevations in the oral glucose tolerance test.?KY-226 also increased pIR and phosphorylated Akt in the liver and femoral muscle.?In high-fat diet-induced obese mice, the oral administration of KY-226 (30 and 60 mg/kg/day, 4 weeks) decreased body weight gain, food consumption, and fat volume gain with increases in phosphorylated STAT3 in the hypothalamus. |
分子量 | 481.67 |
分子式 | C27H31NO3S2 |
CAS No. | 1621673-53-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (51.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0761 mL | 10.3806 mL | 20.7611 mL | 51.9028 mL |
5 mM | 0.4152 mL | 2.0761 mL | 4.1522 mL | 10.3806 mL | |
10 mM | 0.2076 mL | 1.0381 mL | 2.0761 mL | 5.1903 mL | |
20 mM | 0.1038 mL | 0.519 mL | 1.0381 mL | 2.5951 mL | |
50 mM | 0.0415 mL | 0.2076 mL | 0.4152 mL | 1.0381 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KY-226 1621673-53-7 Metabolism Phosphatase inhibit anti-diabetic leptin ZO-1 LPS insulin KY 226 KY226 phosphorylated Akt anti-obesity PTP1B neurons Inhibitor inhibitor